McKesson (MCK) Expected to Announce Earnings on Wednesday

McKesson (NYSE:MCK) is anticipated to post its Q1 2027 results after the market closes on Wednesday, August 5th. Analysts expect McKesson to post earnings of $9.56 per share and revenue of $103.8786 billion for the quarter. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Parties can find conference call details on the company’s upcoming Q1 2027 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

McKesson (NYSE:MCK) last posted its earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. The firm had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.McKesson’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the company earned $10.12 earnings per share. On average, analysts expect McKesson to post $44 EPS for the current fiscal year and $50 EPS for the next fiscal year.

McKesson Trading Down 3.6%

Shares of MCK stock opened at $825.00 on Tuesday. McKesson has a twelve month low of $637.00 and a twelve month high of $999.00. The stock has a market cap of $96.59 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.41 and a beta of 0.30. The stock has a 50 day moving average of $791.90 and a 200 day moving average of $840.34.

McKesson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, September 1st. This is a positive change from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio is 8.53%.

Analyst Ratings Changes

MCK has been the subject of several recent research reports. Bank of America cut their target price on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a report on Monday, April 6th. Weiss Ratings downgraded shares of McKesson from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. cut their price objective on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Barclays decreased their price objective on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Finally, Citigroup increased their target price on shares of McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $962.67.

Insiders Place Their Bets

In related news, EVP Michele Lau sold 3,550 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $2,471,259.23. The trade was a 52.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total transaction of $101,612.00. Following the transaction, the chief accounting officer owned 632 shares of the company’s stock, valued at $482,848. This represents a 17.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 28,748 shares of company stock valued at $22,262,035. Corporate insiders own 0.06% of the company’s stock.

Institutional Trading of McKesson

A number of institutional investors and hedge funds have recently modified their holdings of the stock. IHT Wealth Management LLC increased its stake in McKesson by 0.9% in the 4th quarter. IHT Wealth Management LLC now owns 1,196 shares of the company’s stock worth $981,000 after acquiring an additional 11 shares during the last quarter. River Wealth Advisors LLC boosted its position in shares of McKesson by 0.9% during the 4th quarter. River Wealth Advisors LLC now owns 1,383 shares of the company’s stock valued at $1,134,000 after acquiring an additional 13 shares during the last quarter. DF Dent & Co. Inc. boosted its position in shares of McKesson by 1.1% during the 4th quarter. DF Dent & Co. Inc. now owns 1,238 shares of the company’s stock valued at $1,016,000 after acquiring an additional 14 shares during the last quarter. Bey Douglas LLC grew its holdings in shares of McKesson by 0.3% in the fourth quarter. Bey Douglas LLC now owns 5,833 shares of the company’s stock valued at $4,785,000 after purchasing an additional 15 shares in the last quarter. Finally, Cynosure Group LLC grew its holdings in shares of McKesson by 2.9% in the fourth quarter. Cynosure Group LLC now owns 568 shares of the company’s stock valued at $466,000 after purchasing an additional 16 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.